{"id":904176,"date":"2025-11-03T10:05:47","date_gmt":"2025-11-03T15:05:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\/"},"modified":"2025-11-03T10:05:47","modified_gmt":"2025-11-03T15:05:47","slug":"indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\/","title":{"rendered":"Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li>\n          <i>Medicaid and commercially insured patients with high adherence to\u00a0SUBLOCADE\u00ae\u00a0experienced\u00a0lower\u00a0relapse\u00a0rates and\u00a0reduced\u00a0healthcare\u00a0resource utilization<\/i>\n        <\/li>\n<li>\n          <i>Adherence to\u00a0SUBLOCADE\u00a0was\u00a0associated\u00a0with\u00a0lower\u00a0rates\u00a0of\u00a0infectious\u00a0disease complications\u00a0and\u00a0improved chronic\u00a0disease\u00a0management\u00a0in\u00a0people\u00a0with\u00a0opioid use disorder (OUD)<\/i>\n        <\/li>\n<\/ul>\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">RICHMOND, Va.<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 3, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Indivior\u00a0PLC\u00a0(Nasdaq:\u00a0INDV) presented\u00a0three\u00a0new scientific posters at the Academy of Managed Care Pharmacy (AMCP) Nexus 2025 conference last week, showcasing real-world evidence on the clinical and economic impact of monthly injectable buprenorphine in the treatment of OUD. The data highlights the potential of SUBLOCADE to improve patient outcomes while reducing healthcare resource utilization across both Medicaid and commercially insured populations.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1814851\/Indivior_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1814851\/Indivior_Logo.jpg\" title=\"Indivior (PRNewsfoto\/Indivior)\" alt=\"Indivior (PRNewsfoto\/Indivior)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>&#8220;These\u00a0new\u00a0findings\u00a0reinforce\u00a0what\u00a0key\u00a0stakeholders\u00a0have\u00a0long\u00a0sought: treatment\u00a0that delivers both better outcomes for patients and greater value for the health system,&#8221; said\u00a0Christian Heidbreder,\u00a0Ph.D.,\u00a0Chief\u00a0Scientific\u00a0Officer at\u00a0Indivior.\u00a0&#8220;When\u00a0patients\u00a0are engaged in treatment, monthly injectable buprenorphine can lessen reliance on emergency and inpatient care and reduce rates of detox visits, creating meaningful value for patients, providers, and payors.&#8221;<\/p>\n<p>\n        <b>Poster\u00a0Highlights<\/b>\n      <\/p>\n<p>1.<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4547101-1&amp;h=49596580&amp;u=https%3A%2F%2Fwww.indivior.com%2Fadmin%2Fresources%2Fdam%2Fid%2F1813%2FAMCP_Nexus_Abstract_Cost_Benefit_Analysis_SUBLOCADE_vs_SOC_%2528Medicaid%2529.pdf&amp;a=Healthcare+resource+utilization+among+patients+with%C2%A0OUD+insured+by+Medicaid+and%C2%A0\" target=\"_blank\" rel=\"nofollow\"><u>Healthcare resource utilization among patients with\u00a0OUD insured by Medicaid and<\/u>\u00a0<\/a><u><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4547101-1&amp;h=198652397&amp;u=https%3A%2F%2Fwww.indivior.com%2Fadmin%2Fresources%2Fdam%2Fid%2F1813%2FAMCP_Nexus_Abstract_Cost_Benefit_Analysis_SUBLOCADE_vs_SOC_%2528Medicaid%2529.pdf&amp;a=treated+with+monthly+injectable+buprenorphine%3A+a+retrospective+claims+analys\" target=\"_blank\" rel=\"nofollow\">treated with monthly injectable buprenorphine: a retrospective claims analys<\/a>is<\/u> Medicaid patients with high adherence to SUBLOCADE, a monthly injectable buprenorphine,\u00a0had\u00a0significantly\u00a0lower\u00a0healthcare\u00a0resource utilization\u00a0compared\u00a0to patients with low adherence, including:<\/p>\n<ul type=\"disc\">\n<li>Lower rates of emergency department visits for any reason (48.3% vs. 65.9%) and OUD-related reasons (3.8% vs. 12.9%);<\/li>\n<li>Lower rates of hospital admissions for any reason (7.7% vs. 18.2%) and for OUD- related reasons (0.1% vs. 0.5%);<\/li>\n<li>Lower rates of detox visits for any reason (9.3% vs. 28.4%) and for\u00a0OUD-related reasons (7.7% vs. 26.5%); and<\/li>\n<li>Lower rates of OUD\u00a0symptom\u00a0recurrence\u00a0(7.6%\u00a0vs.\u00a027.6%).<\/li>\n<\/ul>\n<p>Patients who had low adherence to SUBLOCADE remained, on average, 50% adherent\u00a0to\u00a0treatment\u00a0with\u00a0any\u00a0combination\u00a0of\u00a0buprenorphine\u00a0and\/or\u00a0naltrexone formulations.<\/p>\n<p>2. <u><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4547101-1&amp;h=4135148867&amp;u=https%3A%2F%2Fwww.indivior.com%2Fadmin%2Fresources%2Fdam%2Fid%2F1812%2FAMCP_Nexus2025_Abstract_Cost_Benefit_Analysis_SUBLOCADE_vs_SOC.pdf&amp;a=Healthcare+resource+utilization+and+cost+among+commercially+insured+OUD%C2%A0patients\" target=\"_blank\" rel=\"nofollow\">Healthcare resource utilization and cost among commercially insured OUD\u00a0patients<\/a><\/u>\u00a0<u><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4547101-1&amp;h=12993054&amp;u=https%3A%2F%2Fwww.indivior.com%2Fadmin%2Fresources%2Fdam%2Fid%2F1812%2FAMCP_Nexus2025_Abstract_Cost_Benefit_Analysis_SUBLOCADE_vs_SOC.pdf&amp;a=treated+with+monthly+injectable+buprenorphine%3A+a+retrospective+claims+analysis\" target=\"_blank\" rel=\"nofollow\">treated with monthly injectable buprenorphine: a retrospective claims analysis<\/a><\/u><\/p>\n<p>A\u00a0parallel analysis\u00a0among\u00a0commercially\u00a0insured\u00a0patients\u00a0also\u00a0showed\u00a0that\u00a0higher adherence to SUBLOCADE was associated with improved healthcare resource utilization compared to low adherence, including:<\/p>\n<ul type=\"disc\">\n<li>Fewer emergency room visits for any reason (24.2% vs. 38.9%);<\/li>\n<li>Fewer detox visits (9.6% vs. 20.4%);<\/li>\n<li>Reduced recurrence of\u00a0OUD\u00a0symptoms\u00a0(5.7% vs.\u00a016.7%);\u00a0and<\/li>\n<li>Nearly half the total medical costs (<span class=\"xn-money\">$23,051<\/span> vs. <span class=\"xn-money\">$43,357<\/span>) and\u00a0OUD-related\u00a0costs (<span class=\"xn-money\">$8,975<\/span> vs. <span class=\"xn-money\">$19,623<\/span>) after excluding medications for OUD-related pharmacy costs.<\/li>\n<\/ul>\n<p>These\u00a0findings demonstrate\u00a0that\u00a0SUBLOCADE\u00a0may\u00a0offer\u00a0meaningful\u00a0value\u00a0to\u00a0payors by reducing all-cause and OUD-related healthcare resource utilization and costs.<\/p>\n<p>3. <u><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4547101-1&amp;h=3641316322&amp;u=https%3A%2F%2Fwww.indivior.com%2Fadmin%2Fresources%2Fdam%2Fid%2F1818%2FFinal_Assessment_of_Chronic_Disease_Post_MOUD_Engagement.Abstract.AMCP_Nexus_2025.pdf&amp;a=Impact+of+Medications+for%C2%A0OUD%C2%A0on%C2%A0Infectious%C2%A0Disease+Management\" target=\"_blank\" rel=\"nofollow\">Impact of Medications for\u00a0OUD\u00a0on\u00a0Infectious\u00a0Disease Management<\/a><\/u><\/p>\n<p>A retrospective cohort study found that patients treated with SUBLOCADE experienced larger reductions in the incidence of acute skin infections (37% lower based on unweighted analysis) and bacteremia (62% lower based on weighted analysis)\u00a0compared to\u00a0those\u00a0treated with\u00a0transmucosal\u00a0buprenorphine.\u00a0SUBLOCADE was also associated with reductions in sexually transmitted infection-related outpatient visits (77% lower based on weighted analysis). Increased hepatitis B, hepatitis C, and bone\/joint infection outpatient visits among patients treated with SUBLOCADE may suggest an overall improvement in the chronic management of infectious conditions through regular clinical follow-ups.<\/p>\n<p>Study\u00a0limitations\u00a0include\u00a0the\u00a0retrospective\u00a0nature\u00a0of\u00a0the\u00a0Electronic\u00a0Health Record\u00a0(EHR) and claims data, which may introduce bias, the absence of adjustments for baseline differences between adherence groups, and the inclusion of study periods overlapping with the COVID-19 pandemic, during which restricted access to care and disruptions in the healthcare system may have influenced the findings.<\/p>\n<p>\n        <b>About\u00a0SUBLOCADE\u00ae<\/b>\n      <\/p>\n<p>\n        <b>SUBLOCADE\u00ae\u00a0(buprenorphine\u00a0extended-release)\u00a0injection,\u00a0for\u00a0subcutaneous\u00a0use,\u00a0CIII<\/b>\n      <\/p>\n<p>\n        <b>INDICATION\u00a0AND\u00a0HIGHLIGHTED\u00a0SAFETY INFORMATION <\/b>\n      <\/p>\n<p>\n        <b>INDICATION<\/b>\n      <\/p>\n<p>SUBLOCADE\u00a0is\u00a0indicated\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0moderate\u00a0to\u00a0severe\u00a0opioid use\u00a0disorder\u00a0in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.<\/p>\n<p>SUBLOCADE\u00a0should\u00a0be\u00a0used\u00a0as\u00a0part\u00a0of\u00a0a\u00a0complete\u00a0treatment\u00a0plan\u00a0that\u00a0includes counseling and psychosocial support.<\/p>\n<p>\n        <b>HIGHLIGHTED\u00a0SAFETY\u00a0INFORMATION<\/b>\n      <\/p>\n<p>\n        <b>WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION;\u00a0SUBLOCADE\u00a0RISK\u00a0EVALUATION\u00a0AND\u00a0MITIGATION\u00a0STRATEGY<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>Serious harm or death could result if administered intravenously.\u00a0SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously.<\/b>\n        <\/li>\n<li>\n          <b>Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program call the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements.<\/b>\n        <\/li>\n<\/ul>\n<p>\n        <b>CONTRAINDICATIONS<\/b>\n      <\/p>\n<p>Hypersensitivity\u00a0to\u00a0buprenorphine\u00a0or\u00a0any\u00a0other\u00a0ingredients\u00a0in SUBLOCADE.<\/p>\n<p>\n        <b>WARNINGS\u00a0AND\u00a0PRECAUTIONS<\/b>\n      <\/p>\n<p>\n        <u>Addiction, Abuse, and Misuse<\/u>: SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Monitor patients\u00a0for\u00a0conditions\u00a0indicative\u00a0of\u00a0diversion\u00a0or\u00a0progression\u00a0of\u00a0opioid\u00a0dependence\u00a0and addictive behaviors.<\/p>\n<p>\n        <u>Respiratory Depression<\/u>: Life threatening respiratory depression and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration\u00a0of\u00a0benzodiazepines\u00a0or\u00a0other\u00a0CNS\u00a0depressants\u00a0while\u00a0under\u00a0treatment with SUBLOCADE.<\/p>\n<p>\n        <u>Risk of\u00a0Serious Injection\u00a0Site Reactions<\/u>: Likelihood\u00a0of\u00a0may increase with\u00a0inadvertent intramuscular\u00a0or\u00a0intradermal\u00a0administration.\u00a0Evaluate\u00a0and\u00a0treat\u00a0as\u00a0appropriate.\u00a0The most common injection site reactions are pain, erythema and pruritus with some involving abscess, ulceration and necrosis.<\/p>\n<p>\n        <u>Neonatal\u00a0Opioid Withdrawal\u00a0Syndrome<\/u>:\u00a0Neonatal opioid\u00a0withdrawal\u00a0syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy.<\/p>\n<p>\n        <u>Adrenal\u00a0Insufficiency<\/u>:\u00a0If\u00a0diagnosed,\u00a0treat with\u00a0physiologic\u00a0replacement\u00a0of corticosteroids, and wean patient off of the opioid.<\/p>\n<p>\n        <u>Risk\u00a0of\u00a0Opioid\u00a0Withdrawal\u00a0with\u00a0Abrupt\u00a0Discontinuation<\/u>:\u00a0If\u00a0treatment\u00a0with\u00a0SUBLOCADE\u00a0is discontinued, monitor patients for several months for withdrawal and treat appropriately.<\/p>\n<p>\n        <u>Risk\u00a0of\u00a0Hepatitis,\u00a0Hepatic Events<\/u>:\u00a0Monitor\u00a0liver function\u00a0tests\u00a0prior to\u00a0and\u00a0during treatment.<\/p>\n<p>\n        <u>Risk\u00a0of\u00a0Withdrawal\u00a0in\u00a0Patients\u00a0Dependent on\u00a0Full\u00a0Agonist\u00a0Opioids<\/u>:\u00a0Verify that\u00a0patients have tolerated transmucosal buprenorphine before injecting SUBLOCADE.<\/p>\n<p>\n        <u>Treatment\u00a0of\u00a0Emergent\u00a0Acute\u00a0Pain<\/u>:\u00a0Treat\u00a0pain\u00a0with\u00a0a\u00a0non-opioid\u00a0analgesic\u00a0whenever possible.\u00a0If\u00a0opioid\u00a0therapy\u00a0is\u00a0required,\u00a0monitor patients\u00a0closely\u00a0because higher\u00a0doses may be required for analgesic effect.<\/p>\n<p>\n        <b>ADVERSE REACTIONS<\/b>\n      <\/p>\n<p>Adverse\u00a0reactions\u00a0commonly associated\u00a0with\u00a0SUBLOCADE\u00a0(in\u00a0\u22655%\u00a0of\u00a0subjects)\u00a0were constipation, headache, nausea, injection site pruritus, vomiting, increased hepatic enzymes, fatigue, and injection site pain.<\/p>\n<p>For\u00a0more\u00a0information\u00a0about\u00a0SUBLOCADE,\u00a0the\u00a0full\u00a0Prescribing\u00a0information\u00a0including BOXED WARNING, and Medication Guide, visit <u><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4547101-1&amp;h=463330457&amp;u=https%3A%2F%2Fwww.sublocade.com%2F&amp;a=www.sublocade.com\" target=\"_blank\" rel=\"nofollow\">www.sublocade.com<\/a><\/u>.<\/p>\n<p>\n        <b>About\u00a0Opioid\u00a0Use\u00a0Disorder (OUD)<br \/><\/b>Opioid Use Disorder (OUD) is a chronic disease in which people develop a pattern of using\u00a0opioids that\u00a0can\u00a0lead\u00a0to\u00a0negative consequences.\u00a0OUD\u00a0may\u00a0affect\u00a0the\u00a0parts\u00a0of\u00a0the brain that are necessary for life-sustaining functions.<\/p>\n<p>\n        <b>About\u00a0Indivior<\/b>\n      <\/p>\n<p>Indivior Pharmaceuticals works to help change patients&#8217; lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a human crisis to a recognized and treated chronic disease. Building on its portfolio of OUD\u00a0treatments,\u00a0Indivior has\u00a0a\u00a0pipeline\u00a0of\u00a0product candidates\u00a0designed\u00a0to\u00a0expand\u00a0on\u00a0its heritage in this category. Visit <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4547101-1&amp;h=198249254&amp;u=http%3A%2F%2Fwww.indivior.com%2F&amp;a=www.indivior.com\" target=\"_blank\" rel=\"nofollow\">www.indivior.com<\/a> to learn more. Connect with Indivior\u00a0on LinkedIn by visiting <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4547101-1&amp;h=478849344&amp;u=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2FIndivior&amp;a=www.linkedin.com%2Fcompany%2FIndivior.\" target=\"_blank\" rel=\"nofollow\">www.linkedin.com\/company\/Indivior.<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=PH12843&amp;sd=2025-11-03\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine-302601619.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine-302601619.html<\/a><\/p>\n<p>SOURCE  Indivior PLC<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PH12843&amp;Transmission_Id=202511030800PR_NEWS_USPR_____PH12843&amp;DateId=20251103\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Medicaid and commercially insured patients with high adherence to\u00a0SUBLOCADE\u00ae\u00a0experienced\u00a0lower\u00a0relapse\u00a0rates and\u00a0reduced\u00a0healthcare\u00a0resource utilization Adherence to\u00a0SUBLOCADE\u00a0was\u00a0associated\u00a0with\u00a0lower\u00a0rates\u00a0of\u00a0infectious\u00a0disease complications\u00a0and\u00a0improved chronic\u00a0disease\u00a0management\u00a0in\u00a0people\u00a0with\u00a0opioid use disorder (OUD) RICHMOND, Va. , Nov. 3, 2025 \/PRNewswire\/ &#8212; Indivior\u00a0PLC\u00a0(Nasdaq:\u00a0INDV) presented\u00a0three\u00a0new scientific posters at the Academy of Managed Care Pharmacy (AMCP) Nexus 2025 conference last week, showcasing real-world evidence on the clinical and economic impact of monthly injectable buprenorphine in the treatment of OUD. The data highlights the potential of SUBLOCADE to improve patient outcomes while reducing healthcare resource utilization across both Medicaid and commercially insured populations. &#8220;These\u00a0new\u00a0findings\u00a0reinforce\u00a0what\u00a0key\u00a0stakeholders\u00a0have\u00a0long\u00a0sought: treatment\u00a0that delivers both better outcomes for patients and greater value for the health system,&#8221; said\u00a0Christian Heidbreder,\u00a0Ph.D.,\u00a0Chief\u00a0Scientific\u00a0Officer at\u00a0Indivior.\u00a0&#8220;When\u00a0patients\u00a0are engaged in treatment, monthly injectable buprenorphine can lessen reliance on emergency and inpatient care and reduce &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-904176","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Medicaid and commercially insured patients with high adherence to\u00a0SUBLOCADE\u00ae\u00a0experienced\u00a0lower\u00a0relapse\u00a0rates and\u00a0reduced\u00a0healthcare\u00a0resource utilization Adherence to\u00a0SUBLOCADE\u00a0was\u00a0associated\u00a0with\u00a0lower\u00a0rates\u00a0of\u00a0infectious\u00a0disease complications\u00a0and\u00a0improved chronic\u00a0disease\u00a0management\u00a0in\u00a0people\u00a0with\u00a0opioid use disorder (OUD) RICHMOND, Va. , Nov. 3, 2025 \/PRNewswire\/ &#8212; Indivior\u00a0PLC\u00a0(Nasdaq:\u00a0INDV) presented\u00a0three\u00a0new scientific posters at the Academy of Managed Care Pharmacy (AMCP) Nexus 2025 conference last week, showcasing real-world evidence on the clinical and economic impact of monthly injectable buprenorphine in the treatment of OUD. The data highlights the potential of SUBLOCADE to improve patient outcomes while reducing healthcare resource utilization across both Medicaid and commercially insured populations. &#8220;These\u00a0new\u00a0findings\u00a0reinforce\u00a0what\u00a0key\u00a0stakeholders\u00a0have\u00a0long\u00a0sought: treatment\u00a0that delivers both better outcomes for patients and greater value for the health system,&#8221; said\u00a0Christian Heidbreder,\u00a0Ph.D.,\u00a0Chief\u00a0Scientific\u00a0Officer at\u00a0Indivior.\u00a0&#8220;When\u00a0patients\u00a0are engaged in treatment, monthly injectable buprenorphine can lessen reliance on emergency and inpatient care and reduce &hellip; Continue reading &quot;Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T15:05:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1814851\/Indivior_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine\",\"datePublished\":\"2025-11-03T15:05:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\\\/\"},\"wordCount\":1193,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1814851\\\/Indivior_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\\\/\",\"name\":\"Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1814851\\\/Indivior_Logo.jpg\",\"datePublished\":\"2025-11-03T15:05:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1814851\\\/Indivior_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1814851\\\/Indivior_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\/","og_locale":"en_US","og_type":"article","og_title":"Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine - Market Newsdesk","og_description":"PR Newswire Medicaid and commercially insured patients with high adherence to\u00a0SUBLOCADE\u00ae\u00a0experienced\u00a0lower\u00a0relapse\u00a0rates and\u00a0reduced\u00a0healthcare\u00a0resource utilization Adherence to\u00a0SUBLOCADE\u00a0was\u00a0associated\u00a0with\u00a0lower\u00a0rates\u00a0of\u00a0infectious\u00a0disease complications\u00a0and\u00a0improved chronic\u00a0disease\u00a0management\u00a0in\u00a0people\u00a0with\u00a0opioid use disorder (OUD) RICHMOND, Va. , Nov. 3, 2025 \/PRNewswire\/ &#8212; Indivior\u00a0PLC\u00a0(Nasdaq:\u00a0INDV) presented\u00a0three\u00a0new scientific posters at the Academy of Managed Care Pharmacy (AMCP) Nexus 2025 conference last week, showcasing real-world evidence on the clinical and economic impact of monthly injectable buprenorphine in the treatment of OUD. The data highlights the potential of SUBLOCADE to improve patient outcomes while reducing healthcare resource utilization across both Medicaid and commercially insured populations. &#8220;These\u00a0new\u00a0findings\u00a0reinforce\u00a0what\u00a0key\u00a0stakeholders\u00a0have\u00a0long\u00a0sought: treatment\u00a0that delivers both better outcomes for patients and greater value for the health system,&#8221; said\u00a0Christian Heidbreder,\u00a0Ph.D.,\u00a0Chief\u00a0Scientific\u00a0Officer at\u00a0Indivior.\u00a0&#8220;When\u00a0patients\u00a0are engaged in treatment, monthly injectable buprenorphine can lessen reliance on emergency and inpatient care and reduce &hellip; Continue reading \"Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-03T15:05:47+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1814851\/Indivior_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine","datePublished":"2025-11-03T15:05:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\/"},"wordCount":1193,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1814851\/Indivior_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\/","name":"Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1814851\/Indivior_Logo.jpg","datePublished":"2025-11-03T15:05:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1814851\/Indivior_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1814851\/Indivior_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indivior-presents-new-real-world-evidence-at-amcp-nexus-2025-demonstrating-clinical-and-economic-benefits-of-adherence-to-monthly-injectable-buprenorphine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=904176"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904176\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=904176"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=904176"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=904176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}